



J. B. Chemicals & Pharmaceuticals Limited

**J. B. Chemicals & Pharmaceuticals Limited
Announces Audited Financial Results for FY 2006-07.**

**Turnover Up 14%
Total Dividend 130% - Recommends 75% Final Dividend**

BSE Scrip Code: 506943

NSE Symbol: JBCHEPHARM

Mumbai, May 16, 2007: J. B. Chemicals & Pharmaceuticals Limited (JBCPL) today announced its Audited Financial Results for the Financial Year ended March 31, 2007.

The Company has achieved Net Sales of Rs. 531.46 crores as against Rs.466.00 crores in the previous year, registering a growth of 14%. Interest is at Rs.11.25 crores (Rs.5.40 crores). Depreciation claims Rs. 11.33 crores (Rs.10.73 crores) and Provision for Taxation is Rs. 4.20 crores (Rs.9.79 crores). Deferred Tax is Rs. 3.35 crores (Rs.1.16 crores). Fringe Benefit Tax is Rs. 1.20 crores (Rs.1.50 crores). The Profit after Taxation for the year is Rs. 71.02 crores (Rs.70.93 crores), registering an increase of 0.13%. The EBIDTA for the year is Rs. 102.36 crores (Rs. 99.45 crores) registering an increase of 2.92%.

Profit brought forward from the previous year is Rs. 17.50 crores, hence Profit available for appropriation is Rs.88.52 crores. The dividend pay-out including the Dividend Distribution Tax will claim Rs. 25.37 crores (Rs.24.49 crores). The amount transferred to General Reserve is Rs. 43.15 crores (Rs. 41.44 crores). Profit carried forward is Rs. 20.00 crores (Rs.20.00 crores). The total Reserves and Surplus works out to Rs. 404.26 crores as against Rs. 317.01 crores at the end of the previous year. The Basic Earnings Per Share on a capital of Rs.16.87 crores, is Rs. 8.44 (Rs.8.83) on a face value of Rs.2/- per share.

For the financial year ended 31st March 2007, the Board of Directors has recommended Final Dividend of Rs. 1.50 (75%) per Equity Share, on Nominal Value of Rs.2/- per share, on an enhanced Equity Share Capital of Rs. 16.87 crores. Considering the Interim Dividend of Rs.1.10 (55%) already paid the total dividend for the FY 2006-07 paid/recommended is 130%, which works-out to around 36% (including DDT) of PAT.

The Register of Members and Share Transfer Books will remain closed from July 16, 2007 to July 27, 2007 (both days inclusive) for ascertaining the Members who are entitled for payment of Final Dividend 2006-07.

In Q4 FY06-07, the Company achieved Net Sales of Rs.142.74 crores as compared with Rs.114.12 crores for the same period last year registering a growth of 25%, while Profit After Tax stood at Rs.10.93 crores (Rs.15.46 crores).

The Net Profit for the FY 2006-07 would have been higher but for the significant investments made in Marketing (Domestic, Russia & CIS countries) including promotional personnel, foreign exchange fluctuation loss and higher financing cost.

The Company's Large and Small volume parentals facilities in Panoli, Gujarat, built as per international cGMP standard and the captive power plant for generation of electricity commenced commercial production w.e.f. March 24, 2007. The Company has made sizeable investment of Rs.79.42 crore in building infrastructure at Panoli. These investments are expected to yield results in the coming years.

The Company made a major break through by acquiring 49% equity stake in Biotech Laboratories (Pty) Ltd. (Biotech) for USD 5.1 mn. through J. B. Healthcare Pvt. Ltd., Jersey, Channel Islands. This strategic investment will strengthen the Company's position in South Africa in terms of participation in government and sector related tenders. Moreover, it will help the Company to tap lucrative high growth South African and other African markets through launch of its ethical and OTC range of products including Doktor Mom.

To further consolidate its position in Russia, the Company had set-up a warehouse under the banner of 'OOO Unique Pharmaceutical Laboratories' a Wholly Owned Subsidiary in Moscow, Russia. With this initiative the Company expects to grow its market share in Russia and maintain its leadership position with the aggressive marketing strategy.

In domestic market the Company has created a new SBU in the name of 'AUSTER' to increase focus on therapeutic segments like Gastroenterology, Cardiology and Orthopedic. As a part of its growth plan, the Company has launched two new products in Osteoporosis segment in Rs.125.00 crores market, Methylprednisolone in Rs.129.00 crores steroid market, and one Laxative in Rs.145.00 crores market, besides four brands in Ophthalmologicals market of Rs.369.00 crores. With this, Company's representation in the domestic market has increased to 48.9% from 42.8%.

During FY 2007-08 the Company will continue its aggressive pursuit to harness opportunities in Domestic as well as Global markets with a strong focus on markets having strong growth potential such as South Africa, Australia and Latin America.

For more information on JBCPL visit our website at www.jbcpl.com

-- x --

For more details, please contact:

Beejal Desai

Vice President & Company Secretary

Head Investor Relations

J. B. Chemicals & Pharmaceuticals Ltd.

91 22 2499 1311

Forward Looking Statements:

This Press Release may contain Forward Looking Statements regarding future events and future performance of J.B. Chemicals & Pharmaceuticals Ltd. that involve risks and uncertainties that could cause actual results to differ materially from those that may be indicated by such statements.